Skip to main content
. 2023 Aug 5;14:4716. doi: 10.1038/s41467-023-40203-2

Fig. 4. ARID1A overexpression in cardiomyocytes enhances maturation of engineered human myocardium.

Fig. 4

A Schematic overview of cardiomyocyte differentiation and transduction with Lenti-ARID1A (or Lenti-GFP as control) and casting with human foreskin fibroblasts (HFF) to generate engineered human myocardium (EHM). Contraction force and kinetics measurements were performed weekly for 4 weeks. B Quantification of ARID1A RNA by qPCR (left, n = 2 independent differentiations, with 4 technical replicates each), western blot (middle) and quantification of ARID1A protein level (right; P = 0.0022, two-tailed Student’s t-test on average of 4 independent differentiations; graph shows 4 independent differentiations, with 2 or 3 replicates each); (**P < 0,01, two-tailed Student’s t-test) in iPS-CM transduced with Lenti-ARID1A or Lenti-GFP. Molecular weight marker (kDa) is shown at the right. C Representative images of EHM tissue (left) and GFP fluorescence (right) at the end of the experiment showing sustained expression of the Lentiviral cargo. DF EHM contraction measurements, n = 10 engineered human myocardium rings from a single experiment; *P < 0.05, **P < 0.01, ****P < 0.0001, two-tailed Student’s t-test, performed separately for each timepoint. D Force of contraction (F; P = 0.0380) measurements of Lenti-GFP or Lenti-ARID1A EHM at 4 weeks after casting. E Contraction time(P < 0.0001), relaxation time (P = 0.0225), and contraction frequency (P = 0.6375) at 4 weeks (n = 10; *P < 0.05, two-tailed Student’s t-test). F Force of contraction (left) and contraction velocity (dF/dt) measurements over time. Graphs show mean with standard error of the mean. Source data are provided as a Source Data file. A Created with BioRender.com.

HHS Vulnerability Disclosure